Tomer Meirson
Oct 1, 2020
Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
Bomze D, Asher N, Hasan A, Flatz L, Azoulay D, Markel G, Meirson T. Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors. JAMA Netw Open 2020; 3:e2017675.
Oct 1, 2020Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
Oct 1, 2020JAMA Netw Open 2020; 3:e2017675
Bomze David, Asher Nethanel, Hasan Ali, Flatz Lukas, Azoulay Daniel, Markel Gal, Meirson Tomer
more
Aug 4, 2020
Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis
Bomze D, Meirson T, Hasan A, Goldman A, Flatz L, Habot-Wilner Z. Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis. Ocul Immunol Inflamm 2020:1-7.
Aug 4, 2020Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis
Aug 4, 2020Ocul Immunol Inflamm 2020:1-7
Bomze David, Meirson Tomer, Hasan Ali, Goldman Adam, Flatz Lukas, Habot-Wilner Zohar
more